Joshua Winograd, John Lama, Alia Codelia-Anjum, Naeem Bhojani, Dean S Elterman, Kevin C Zorn, Eric Margolis, Jamin Brahmbhatt, Ricardo Gonzalez, Bilal Chughtai
{"title":"Measuring the efficacy of Serenoa repens (USPlus) extract with mobile uroflowmetry.","authors":"Joshua Winograd, John Lama, Alia Codelia-Anjum, Naeem Bhojani, Dean S Elterman, Kevin C Zorn, Eric Margolis, Jamin Brahmbhatt, Ricardo Gonzalez, Bilal Chughtai","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Benign prostatic hyperplasia (BPH) is a prevalent condition affecting a significant portion of the male population, leading to secondary lower urinary tract symptoms (LUTS). Alternative therapies such as phytotherapy using Lipidosterolic extract of Serenoa repens (LSESR USPlus) are commonly used. However, the efficacy of LSESr remains controversial due to conflicting data. We sought to determine the effect of a standardized USP-verified Saw Palmetto extract on male LUTS secondary to BPH.</p><p><strong>Materials and methods: </strong>In this prospective single-arm trial, we investigated the efficacy of a standardized USP-verified Saw Palmetto extract in treating male LUTS secondary to BPH. We utilized the ProudP mobile application for home uroflowmetry and symptom assessment.</p><p><strong>Results: </strong>Results from 46 patients using 320 mg daily of USP-verified Saw Palmetto extract revealed significant improvements in IPSS and QoL scores at 12 weeks compared to baseline, particularly in patients with moderate symptoms. Uroflowmetry parameters also improved with increased flow rates, primarily in patients with mild symptoms.</p><p><strong>Conclusion: </strong>Our findings support the efficacy of USP-verified Saw Palmetto extract in alleviating LUTS in men with BPH. Further studies are warranted in larger, diverse cohorts over longer follow up periods.</p>","PeriodicalId":56323,"journal":{"name":"Canadian Journal of Urology","volume":"31 6","pages":"12053-12059"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Urology","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Benign prostatic hyperplasia (BPH) is a prevalent condition affecting a significant portion of the male population, leading to secondary lower urinary tract symptoms (LUTS). Alternative therapies such as phytotherapy using Lipidosterolic extract of Serenoa repens (LSESR USPlus) are commonly used. However, the efficacy of LSESr remains controversial due to conflicting data. We sought to determine the effect of a standardized USP-verified Saw Palmetto extract on male LUTS secondary to BPH.
Materials and methods: In this prospective single-arm trial, we investigated the efficacy of a standardized USP-verified Saw Palmetto extract in treating male LUTS secondary to BPH. We utilized the ProudP mobile application for home uroflowmetry and symptom assessment.
Results: Results from 46 patients using 320 mg daily of USP-verified Saw Palmetto extract revealed significant improvements in IPSS and QoL scores at 12 weeks compared to baseline, particularly in patients with moderate symptoms. Uroflowmetry parameters also improved with increased flow rates, primarily in patients with mild symptoms.
Conclusion: Our findings support the efficacy of USP-verified Saw Palmetto extract in alleviating LUTS in men with BPH. Further studies are warranted in larger, diverse cohorts over longer follow up periods.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
